

**PROTECT RCT DATA UPDATE**  
Results from the 1-Year Data Set  
January 2024

**PROTECT**

**NaturalVue:  
PROTECT RCT Offers Data in Myopia  
Correction and Protection**

**PROTECT:  
PROgressive Myopia Treatment  
Evaluation for NaturalVue Multifocal  
Contact Lens Trial**


The study is designed to investigate and quantify the safety and effectiveness of NaturalVue® Multifocal Contact Lenses for myopia progression control in children. PROTECT is a 145-subject, multi-center, double-masked, randomized controlled trial with participating investigators in centers in Canada, the United States, Hong Kong, and Singapore.



# The Results (1-Year Data Set)

## New Data:

### Distribution of Change in Refractive Error (D) in Patients



### Refractive Error

**71%**  
**0.41 D**

#### Average reduction in refractive error progression

- The average refractive error reduction was 71%, or 0.41 D vs. control group for year one.

**0.17 D**

#### Average refractive error change

- Children wearing NaturalVue Multifocal showed an average refractive error change of 0.17 D.

### Axial Length

**0.17 mm**  
**61%**

#### Average reduction in axial elongation

- The average axial length reduction was 0.17 mm (61%) vs. control group for year one.

**0.11 mm**

#### Average axial length change

- The average axial length change in children wearing NaturalVue Multifocal was 0.11 mm.

- Published real-world data indicates Year 2 myopia progression data **likely to trend closely** with Year 1 values.
- Combined with the 6-year data previously published in Clinical Ophthalmology in 2022, and the analysis from 3 independent studies released in September, the one-year data suggests NaturalVue Multifocal may **effectively manage eye growth and refractive error change among children under diverse clinical settings and populations.**

Note: This reflects the 1-year data set. The PROTECT study is ongoing and the data will continue to be reviewed and analyzed with additional details to be shared as available.

This information may describe uses for this product, i.e., Myopia Progression Control, which have not been approved by the FDA for use in the United States and is intended for educational purposes only. NaturalVue® Multifocal is part of an ongoing clinical trial (RCT) that is studying its effectiveness for myopia progression control.